Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novo Nordisk A/S | OZEMPIC (semaglutide) - (EVOKE) | Alzheimer’s disease | Phase 3 | Data Released | Subcutaneous | Neurology |
| Novo Nordisk A/S | Ziltivekimab - (ZEUS) | Chronic Kidney Diseases | Phase 3 | Trial Completed | Intravenous | N/A |
| Novo Nordisk A/S | Icosema - (COMBINE 3) | Type 2 diabetes | Phase 3 | Trial Completed | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Insulin icodec (LAI287) - (ONWARDS 2) | Diabetes | Phase 3 | Trial Completed | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Mim8 - (FRONTIER3) | Hemophilia A | Phase 3 | Data Released | Subcutaneous | Hematology |
| Novo Nordisk A/S | Amycretin - (AMAZE) | Obesity | Phase 3 | Trial Planned | Topical | Endocrinology |
| Novo Nordisk A/S | Semaglutide 7.2 mg - (STEP UP) | Obesity | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Semaglutide - (SOUL) | Major adverse cardiovascular events (MACE) | Phase 3 | Trial Completed | Subcutaneous | Cardiology |
